**Core Concept**
The question tests the understanding of **Hypertrophic Obstructive Cardiomyopathy (HOCM)** and its management, focusing on pharmacological contraindications. HOCM is characterized by asymmetric septal hypertrophy, which can lead to left ventricular outflow tract obstruction.

**Why the Correct Answer is Right**
Although the specific options are not provided, typically, drugs that increase contractility or reduce ventricular volume are contraindicated in HOCM because they can worsen the obstruction. For instance, **positive inotropes** like digoxin can increase the contractility of the heart, potentially exacerbating the obstruction in the left ventricular outflow tract.

**Why Each Wrong Option is Incorrect**
**Option A:** Would be incorrect if it were a drug that does not typically worsen HOCM symptoms.
**Option B:** Similarly, if this option were a beta-blocker, it would be incorrect because beta-blockers are often used to manage HOCM by reducing heart rate and contractility, thus alleviating obstruction.
**Option D:** If this were a drug like verapamil, a calcium channel blocker, it might be considered incorrect in this context, as it can sometimes be used in HOCM management, especially for symptoms not responsive to beta-blockers.

**Clinical Pearl / High-Yield Fact**
A crucial point to remember is that **beta-blockers** are the first-line treatment for HOCM symptoms due to their ability to decrease the heart rate and reduce contractility, thereby lessening the obstruction.

**Correct Answer:** Not provided in the query.